Biotronik Launches 3 Tesla Full-Body MR Conditional ICD and CRT-D Devices in Europe
Biotronik recently announced the European release of the world's smallest ICD and CRT-D devices approved for 3 Tesla full-body MRI scans. The two devices, the Acticor and Rivacor, are only 10mm slim, with a smooth and elliptical BIOshape that facilitates the insertion procedure.
- Acticor and Rivacor devices feature an extended battery life, with up to 15 years for ICDs and nine years for CRT-Ds, which lowers the need for device replacements, resulting in reduced risks and fewer procedure costs.
- All Acticor and Rivacor devices feature ProMRI, allowing patients to have full access to high-resolution 3 Tesla MRI without any exclusion zone.
- The devices all come equipped with sensor-based MRI AutoDetect technology, which can be activated for a programmable window of up to 14 days. This allows the devices to automatically recognize an MR environment and switch in and out of MRI mode as required. Additionally, Acticor and Rivacor devices also feature DX technology, enabling complete atrial diagnostics without an atrial lead.
- During Cardiac resynchronization therapy (CRT), 30-40% of all patients are non-responsive. Acticor anD Rivacor CRT-Ds counter this by featuring CRT AutoAdapt to fit patients’ individual pacing needs and provide continuous CRT adaptation – automatically adjusting to changes sensed in a patient’s condition every minute.
- Cardiovascular data is transferred to physicians on a daily basis through BIOTRONIK Home Monitoring. During the IN-TIME randomized controlled trial, there was more than a 60% reduction in all-cause mortality when CRT-Ds are used with BIOTRONIK Home Monitoring. Both Acticor and Rivacor can utilize the home monitoring capabilities.
“The slenderness and smoother shape of the new devices play a key role in easing the insertion procedure and improving how the device looks after implantation,” reported Dr. Iain Matthews, Northumbria Healthcare, UK, following his first implantations of the devices. More than 90% of implanting physicians rated “patient comfort” as “better” or even “much better” in comparison with previous models during post-market observation.